MRCB Breakout From DT Line - Good Price to EntryThis undervalued construction and property player in Malaysia, MRCB has shown good performance recently. Pullback from the 52Wk high at 0.705, the price now stabilize around 0.56 to 0.59.
The intrinsic value for Malaysian Resources Corporation Berhad is RM9.91 based on Discounted Cash Flow Valuation, that is discounted 94.2% from current price.
Price now recently break from downtrendline (refer chart) and need to break MID BB (MA20) at daily timeframe to confirm the uptrend mood. My price target using fibo is at TP1 D: RM0.795, TP2 D: RM1.03
Hold for long term investment! cheers
Mrcb
MRCB Major Support & ResistancePersonally, what I learnt is there must be a Technical Analysis Strategic Plan in order to increase the risk-to-ratios favourable risks.
1. Draw Support & Resistance
2. Identify the stages (Accumulation, Advancing, Distribution, Declining)
3. Entry Triggers
4. Stop Loss
5. Exits
I have learnt during my past mistakes that we should let the stock price comes to us, rather than us chasing the stock prices!
MRCB Major Support & ResistancePersonally, what I learnt is there must be a Technical Analysis Strategic Plan in order to increase the risk-to-ratios favourable risks.
1. Draw Support & Resistance
2. Identify the stages (Accumulation, Advancing, Distribution, Declining)
3. Entry Triggers
4. Stop Loss
5. Exits
I have learnt during my past mistakes that we should let the stock price comes to us, rather than us chasing the stock prices!
MRCB potential to go upAfter releasing an excellent QR report (QoQ: +2824%) on 25-Feb, MRCB looking good to go upside.
Price just crossed EMA50 with solid volume.
Future Ichi cloud narrowed and looking to turn green.
The first resistance is down trendline or EMA200, if break, potential to swing long.
MCRB - Bounce Trend In Flow - Can It Carry On?Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
SHORT INTEREST
4.91M 07/31/19
P/E Current
-1.22
P/E Ratio (with extraordinary items)
-1.71
Average Recommendation: OVERWEIGHT
Average Target Price: 9.60